Overview

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Ketamine